Table 1.
Demographic and Clinical Characteristics for FEP and HC for Each Site
| Chengdu, China (N = 222) | London, England (N = 142) | Santander A, Spain (N = 220) | Santander B, Spain (N = 210) | Utrecht, The Netherlands (N = 162) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| HC | FEP | HC | FEP | HC | FEP | HC | FEP | HC | FEP | ||
| n | 111 | 111 | 71 | 71 | 110 | 110 | 70 | 140 | 81 | 81 | |
| Gender (%) | M | 51 (46) | 51 (46) | 36 (51) | 36 (51) | 68 (62) | 68 (62) | 45 (64) | 90 (64) | 64 (79) | 64 (79) |
| F | 61 (54) | 61 (54) | 35 (49) | 35 (49) | 42 (38) | 42 (38) | 25 (46) | 50 (46) | 17 (21) | 17 (21) | |
| χ2 = ns | χ2 = ns | χ2 = ns | χ2 = ns | χ2 = ns | |||||||
| Age M (SD) | 27.2 (7.3) | 25.7 (8.1) | 26.8 (7.1) | 26.4 (6.2) | 29.7 (7.8) | 28.5 (8.6) | 27.3 (7.5) | 28.3 (7.6) | 26.9 (8.0) | 25.2 (5.9) | |
| t = ns | t = ns | t = ns | t = ns | t = ns | |||||||
| TIV (L) M (SD) | 1.5 (0.1) | 1.5 (0.2) | 1.5 (0.2) | 1.5 (0.2) | 1.5 (0.1) | 1.4 (0.2) | 1.5 (0.1) | 1.5 (0.1) | 1.6 (0.1) | 1.5 (0.2) | |
| t = ns | t = ns | t = ns | t = ns | t = ns | |||||||
| Positive symptoms M (SD) | — | 24.6 (6.6)a | — | 13.9 (5.5)a | — | 14.7 (4.6)b | — | 14.4 (4.1)b | — | 15.9 (6.3)a | |
| Negative symptoms M (SD) | — | 18.2 (7.7)a | — | 16.0 (6.0)a | — | 6.3 (4.6)c | — | 6.1 (5.0)c | — | 16.2 (6.9)a | |
| Duration of illness (years) Med (IQR) | — | 0.3 (1.1) | — | 1.1 (0.3) | — | 0.3 (0.7) | — | 0.3 (0.9) | — | 0.6 (1.0) |
Note: TIV, total intracranial volume; L, liters; M, male; F, female; FEP, first episode psychosis; HC, healthy controls, SD, standard deviation; Med, median; IQR, interquartile range.
aPANSS: Positive and Negative Symptoms Scale.
bSAPS: Scale for the Assessment of Negative Symptoms.
cSANS: Scale for the Assessment of Negative Symptoms.
ns: P > .05